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Introduction
In Canada, abortion is a safe, common and legal reproductive 
health procedure. One in 3 Canadian individuals who become 
pregnant will experience at least 1 abortion during their repro-
ductive years.1,2 Nevertheless, access to abortion services has not 
been equitable nationwide.2,3 In 2012, approximately 300 phy-
sicians in Canada provided abortion services, predominately 
surgical abortions (96%), at 94 facilities primarily located in 
major cities and urban centres.2-4 Patients living outside of urban 
centres may experience onerous barriers to timely abortion 
access related to travel, financial disparities and significant wait 
times.3,5,6 In January 2017, mifepristone 200 mg/misoprostol 
800 mcg (Mifegymiso) for medical abortion became available in 
Canada, offering an opportunity to address inequities in access-
ing abortion care.3 Internationally, provider training, reduced 
financial burdens and expanded eligible prescribers (e.g., family 
physicians, nurse practitioners, etc.) have enhanced the success-
ful implementation and uptake of this innovation.3,7-10 When 
Health Canada eliminated several restrictions to mifepristone/
misoprostol provision,11 including physician-only dispensing 
and mandatory prescriber training in November 2017, pharma-
cists became an integral part of abortion provision.12,13 Never-
theless, uptake of mifepristone prescribing across the country 
continued to be variable3 and pharmacists experienced barriers 
to providing care to their patients.11
We recognized that novel educational and dispensing 
resources were needed to support the expanded role of Cana-
dian pharmacists in medical abortion care.3,11 We aimed to 
develop an effective and efficient Pharmacist Checklist and 
Resource Guide to promote consistent dispensing of mifepris-
tone and facilitate widespread adoption of medical abortion 
services in community pharmacy practice.
Methods
Our study is embedded in an observational mixed-methods 
research program, the Contraception and Abortion Research 
Team (CART)–Mifepristone Implementation Study.3 Our 
research approach was guided by user-centred design prin-
ciples, a well-established method for rapid innovation design 
with direct input and preferences from “end-users” of a 
Knowledge Into PractIce 
 • community pharmacists in canada are able to dis-
pense mifepristone/misoprostol for medical abortion 
when prescribed by a health professional, such as a 
physician or nurse practitioner.
 • our study demonstrates the usability and acceptability 
of the newly developed Pharmacist checklist for Medi-
cal abortion and the Pharmacist resource guide for 
Medical abortion created by and for pharmacists.
 • the Pharmacist checklist for Medical abortion and the 
Pharmacist resource guide for Medical abortion have 
the potential to enhance the timely provision of sys-
tematic pharmacist counselling for medical abortion, 
ensuring patients consistently receive high-quality guid-
ance and support for managing their medical abortion 
health care needs.
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product or service through ideation, rapid prototyping and 
iterative revisions based upon strengths and weaknesses of 
prototypes.14,15 We divided development and testing into 2 
phases: 1) expert development of pilot prototypes and 2) multi-
method usability testing of iterative prototypes (i.e., interviews, 
surveys) after each of the 3 rounds of revisions.
Phase 1: Checklist and resource guide development
We created the Pharmacist Checklist and Resource Guide pro-
totypes by adapting content from the 2016 Medical Abortion 
Guidelines by the Society of Obstetricians and Gynecologists of 
Canada (SOGC)16 and the Health Canada Product Monograph 
for Mifegymiso.17 Four CART members, including pharmacist 
and physician content experts, reviewed prototypes via email. 
One team member (N.R.) documented recommended modi-
fications, and revised versions were circulated until consensus 
was reached on user testing materials.
Phase 2: Pharmacist usability testing
We invited practising pharmacists in urban and rural settings 
within western Canada to participate. We emailed invitations to 
preidentified content experts and encouraged them to identify 
eligible peers, using a snowball approach. We performed itera-
tive user testing and revision in 3 rounds: first with pharmacy 
practice educators, followed by 2 rounds with community phar-
macists. After participants provided written informed consent 
and basic sociodemographic information (age, gender, phar-
macy position), we emailed them the Pharmacist Checklist and 
Resource Guide. We instructed participants to familiarize them-
selves with the resources and provided close-ended questions for 
their consideration (e.g., Is the information provided complete?). 
Pharmacists participated in 30- to 60-minute telephone or in-
person interviews with a single interviewer (N.R.). Interviews 
used a concurrent think-aloud approach developed by Ericsson 
and Simon,18 encouraging participants to describe their thought 
process while navigating the materials line by line. Participants 
were probed with specific questions about content, layout, lan-
guage and ease of use of the materials as well as the feasibility 
of implementing the materials into their existing pharmacy 
workflow. We adapted the interview protocol and probes from 
our previous user-centred design studies.19,20 Interviews were 
audio-recorded and transcribed verbatim. The interviewer took 
detailed field notes and encouraged participants to make notes on 
the materials and return marked-up copies to the research team. 
After interview completion, participants verbally responded to 
a questionnaire comprised of an adapted System Usability Scale 
(SUS),21 a validated set of 10 statements scored on a 5-point scale 
used to assess a variety of health care technologies (e.g., decision 
aids)22-24 and an adjective rating scored on a 7-point scale from 
“Worst”‘ to “Best imaginable.”25 Total SUS scores range from 0 to 
100, with higher scores indicating increased user-friendliness.25 
We continued collecting data until no new usability issues were 
identified by participants or the research team.
After each interview, the interviewer reviewed field notes 
and participant notations to identify usability issues, list modi-
fiable changes and revise the materials as appropriate. At least 
1 additional team member reviewed modifications to the study 
materials to ensure that changes were clinically accurate. We 
used inductive content analysis to analyze the transcripts, an 
approach that aims to produce replicable and valid conclusions 
generating knowledge, novel insights and practical solutions.26 
Initially, we used line-by-line coding to identify the scope of 
usability concepts, followed by focused coding and constant 
comparison to identify patterns and similarities within and 
between interviews. Codes were clustered into categories. Cat-
egories addressing related concepts were grouped into themes. 
We calculated demographic statistics and mean SUS and adjec-
tive rating scores after each round of testing. Generally, a SUS 
score above 70 is passable, high-quality scores are 70 to 80 and 
superior products score above 90.25 The adjective rating scale 
closely matches the SUS scale and provides a subjective label 
for a product’s SUS score.25
This study received ethics approval from the University of 
British Columbia Behavioural Research Ethics Board.
Results
Twelve participants (2 educators, 10 community pharmacists) 
from 9 western Canadian communities participated in usabil-
ity testing between July 2017 and August 2018 (Table 1). The 
participants’ mean age was 41, half were female and they held 
a range of community and academic pharmacy positions (e.g., 
full-time, part-time, pharmacy manager, pharmacy educator).
Modifying the pharmacist tools for medical abortion
Table 2 presents findings from the usability questionnaire. 
The mean SUS scores were similar between community phar-
macist evaluations (Round 2: 89.0, SD = 9.1; Round 3: 88.0, 
SD = 10.7). The mean adjective rating score (Round 2: 6.2, 
SD = 0.5; Round 3: 5.6, SD = 0.6, where a score of 6 corre-
sponds to “Excellent”) reflected previously reported correla-
tions with mean SUS scores.25
Content analysis of interview transcripts identified modifi-
able changes for improving the usability of materials. Two usabil-
ity themes, “information delivery” and “layout,” were discussed 
and addressed in subsequent revisions. Appendix 1 (available 
online at www.cpjournal.ca) summarizes modified items, pro-
vides rationale-guiding changes and identifies when feedback 
leading to major (e.g., addition of new content) and minor (e.g., 
language use, amount of information) revisions was provided.
Information delivery. Pharmacists identified 4 categories 
related to information delivery: 1) content, 2) integration 
of information between checklist and guide, 3) integration 
of information with other resources and 4) language use. 
Pharmacists wanted the Checklist (Figure 1; see online Appendix 
2 for French version) to focus on the required protocol for 
1 6 8    C P J / R P C  •  m ay / j u n e  2 0 2 1  •  V O L  1 5 4 ,  N O  3
PRACTiCeTOOL
Table 1 Participant characteristics
Characteristics




educators (n = 2)
Round 2:
Community 
pharmacists (n = 5)
Round 3:
Community 
pharmacists (n = 5)
age, mean (Sd) 41 (14) 50 (3) 34 (5) 45 (21)
Female, n (%) 6 (50) 1 (50) 4 (80) 1 (20)
Pharmacy position, n (%)
 Full-time staff pharmacist 5 (42) 0 3 (60) 2 (40)
 Part-time staff pharmacist 2 (17) 1 (50) 0 1 (20)
 Floater pharmacist 1 (8) 0 0 1 (20)
 Store pharmacy manager 5 (42) 0 2 (40) 3 (60)
 Pharmacy owner 4 (33) 0 2 (40) 2 (40)
 Pharmacy educator 2 (17) 2 (100) 0 0
 other 1 (8) 0 0 1 (20)
Table 2 Pharmacist checklist and reference guide usability testing results
Modified system usability scale items

















1. I think that I would like to use these resources frequently. 4.7 (0.9) 4.5 (0.7) 5.0 (0.0) 4.4 (1.3)
2. I found these resources unnecessarily complex. 1.8 (1.3) 3.0 (2.8) 1.8 (1.3) 1.4 (0.6)
3. I think these resources are easy to use. 4.3 (1.2) 3.0 (2.8) 4.6 (0.9) 4.6 (0.6)
4. I think that I would need the support of an expert to be 
able to use these resources.
1.5 (1.0) 1.0 (0.0) 2.2 (1.3) 1.0 (0.0)
5. I found the various components in these resources are 
well integrated.
4.1 (1.4) 3.5 (2.1) 5.0 (0.0) 3.4 (1.5)
6. I think these resources are too inconsistent. 1.4 (0.9) 2.5 (2.1) 1.2 (0.5) 1.2 (0.5)
7. I would imagine that most pharmacists would learn to 
use these resources very quickly.
4.4 (1.2) 3.0 (2.8) 4.8 (0.5) 4.6 (0.6)
8. I found these resources very awkward to use. 1.3 (0.7) 1.0 (0.0) 1.4 (0.9) 1.4 (0.6)
9. I feel very confident using these resources. 4.6 (0.9) 3.5 (2.1) 4.8 (0.5) 4.8 (0.5)
10. I need to learn a lot before I start using these resources. 1.8 (0.8) 1.5 (0.7) 2.0 (1.0) 1.6 (0.6)
total system usability scale score (items 1 to 10) 85.6 (16.3) 71.3 (40.7) 89.0 (9.1) 88.0 (10.7)
11. I would rate the overall user-friendliness of this 
product as (1 = Worst imaginable; 7 = Best imaginable)
5.6 (1.0) 4.0 (1.4) 6.2 (0.5) 5.6 (0.6)
Values are expressed as mean (Sd).
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FiguRe 1 
Pharmacist Checklist for Medical Abortion (MIFEpristone/MISOprostol, Mifegymiso®)  
NOTE: The informaon in this checklist and the accompanying guide is in accordance with the SOGC and Health Canada guidelines for medical aboron with MIFE/MISO.  
I. Pharmacist Prescription Assessment 
NECESSARY  
 Confirm indicaon for medical aboron  
EFFECTIVE  
 Verify appropriate wrien date for prescripon (NOTE: if prescripon was wrien > 7 days, ensure efficacy  
Health Canada indicate use up to 63 days from last menstrual period [LMP]; SOCG up to 70 days LMP) 
 
SAFE  
 Idenfy paent will have access to help (personal support system, transportaon, phone, emergency medical care)  
 Exclude absolute contraindicaons (uncontrolled severe asthma, adrenal failure, allergies, etc)  
 Consider and/or manage relave contraindicaons (IUD, long-term corcosteroid use, hemorrhagic disorders, anemia)  
ADHERENCE   
 Confirm paent is making a clear decision to complete treatment for a medical aboron  
(consider if external pressure is being placed on the paent and if there are feelings of hesitancy; address as required) 
 
 Confirm paent able to take MISO 24-48 hours aer MIFE   
 Confirm paent is able to aend prescriber follow-up 7-14 days aer starng treatment  
II. Patient Counselling  
DIRECTIONS FOR USE – review appropriate administraon   
 Day 1 MIFE (green box label): take 1 tablet orally and swallow with water.  
 Day 2 (24-48 hours) MISO (orange box label): place 4 tablets between the cheek and gum (2 on each side of mouth). Leave in 
place for 30 minutes, then swallow leover fragments with water.  ALWAYS take MISO, even if bleeding starts aer MIFE.  
 
EXPECTED SIDE EFFECT MANAGEMENT AND MONITORING 




  Starts 1-48 hours aer MISO 
      (minimal bleeding aer MIFE) 
  Heavier than menstrual period 
  Heavy bleeding lasts 2-4 hours 
      (light bleeding/spong can last 
un l next menstrual period)  
  May contain blood clots  
  Use sanitary pads for heavy bleeding 
(should diminish upon pregnancy 
termina on) 
  Do not use tampons 
  Use panty liners for light bleeding 
      (up to 30 days aer treatment) 
  Heavy vaginal bleeding (saturates    
> 2 large sanitary pads per hour for 2 
consecu ve hours) 
  Dizziness or racing heart rate 
  Heavy bleeding > 16 days 
  Foul-smelling vaginal discharge 
Pain & 
Cramping 
  Starts within 4 hours of MISO 
  Greater than menstrual period 
  Increased pain up to 24 hours; 
discomfort may persist  
  Comfort care (rest, hot pack, 
abdominal/lower back massage) 
  OTC op ons: ibuprofen, naproxen 
      (acetaminophen is less effec ve alone; 
may be combined with codeine) 
  Prolonged cramping > 16 days 
  Cramping/pain not improved with 
pain medica ons 
Other   Possible gastrointes nal side 
effects (nausea, vomi ng, 
diarrhea), headache, or 
fever/chills  
  Self-limi ng (usually aer MISO) 
  Can manage with OTC op ons     
      (if pregnancy nausea is present, take 
an -nauseant before MIFE and MISO) 
  Can reduce gastrointes nal side 
effects by taking MISO aer a snack   
  Chills/fever > 38°C for > 6 hours 
and malaise (weakness, nausea, 
vomi ng, diarrhea) 
  Feeling sick with/without fever > 24 
hours aer MISO (possible infec on) 
MISSED DOSES 
       If MISO is forgoen and > 48 hours has passed since MIFE: take MISO right away and inform prescriber at follow-up 
       If voming occurs: i. < 1 hour aer taking MIFE or during buccal absorpon of MISO: contact prescriber/pharmacist for assessment  
ii. aer swallowing MISO fragments 30 minutes following buccal administraon: no acon required 
CONSIDERATIONS FOR START DATE   
Refer to schedule in secon 4.4 of the Pharmacist Resource Guide for Medical Aboron 
III. Supportive Care Checklist – ensure your paent has these before leaving… 
  Sanitary pads and liners 
  Pain medicaons and/or an-nauseants (OTC or Rx) 
  Contracepve plan (ferlity can return within 8 days) 
  Scheduled prescriber follow-up  
  Organized personal support (e.g. childcare, transportaon) 
  Reviewed when and where to go for emergency complicaons 
  MIFE start date: dd-mm-yyyy; MISO start date: dd-mm-yyyy       
 




IV. Optional Pharmacist Follow-up (perform 2-3 days aer expected start date) 
Does paent consent to follow-up? date: dd-mm-yyyy at 00:00 AM/PM; method: phone call/text message/e-mail via  number/e-mail 
  Check appropriate administraon  
  Review side effect management 
  Review contracepve plan 
  Reinforce prescriber follow-up  
Pharmacist Signature: 
 
    
     







Pharmacist Checklist for Medical A  (MIFEpristone/MISOprost l, Mifegymiso®) 
NOTE: The information in this checklist and the accompanying guide is in accordance with the SOGC and Health Canada guidelines for medical abortion with MIFE/MISO.
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FiguRe 2 
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dispensing mifepristone/misoprostol and the Resource Guide 
(in English and French, Appendix 3 and 4, available online; see 
Figure 2 for first page of the 6-page document) to provide the 
rationale for the protocol steps. They wanted content within 
these resources to reflect information patients receive from 
other health care sources and recommendations from Canadian 
health care organizations and governing bodies. Pharmacists 
appreciated when language reflected pharmacist-specific 
vocabulary (e.g., NESA: Necessary, Effective, Safe, Adherence) 
and wanted content to follow a pharmacist’s thought process 
when systematically reviewing and dispensing prescriptions. 
After Round 1, the Pharmacist Checklist was subdivided into 
4 parts: 1) Pharmacist Prescription Assessment guided by the 
NESA thought process; 2) Patient Counselling of mifepristone/
misoprostol, including directions for use, missed doses and side 
effect monitoring; 3) Supportive Care Checklist for managing 
side effects and facilitating patients’ reproductive health goals; 
and 4) Optional Pharmacist Follow-up. Recommendations 
for assessing the prescription written date, guidance for 
managing missed doses and the Health Canada and SOGC 
indications for use were added to both documents. After 
Round 2, information to support patient choice of a convenient 
treatment start date, mifepristone/misoprostol nonmedical 
ingredients and a comprehensive list of “Canadian Abortion 
Resources” and support services were added to the Resource 
Guide. After Round 3, space was added for pharmacist’s notes 
in the Pharmacist Checklist. An index and information on 
psychological support were added to the Resource Guide.
Layout. Pharmacists identified 3 categories for visual 
presentation and content arrangement: 1) amount of information; 
2) organization of information; and 3) visual aesthetic. Overall, 
pharmacists agreed the Checklist should be concise, point 
form and limited to a single page. The length of the Resource 
Guide could be longer to ensure inclusion of necessary 
information. After Round 1, pharmacists approved revisions 
of the Checklist organization to reflect pharmacists’ systematic 
thought process and dispensary workflow. After Round 
2, pharmacists welcomed revisions of the Resource Guide 
to reflect the familiar organization of a drug monograph. 
Pharmacists encouraged the use of checkboxes and tables 
to organize practical considerations of complex topics (e.g., 
columns titled “what to expect” and “when to seek help” for 
side effects management), which were incorporated across 
several sections of the resources. Major aesthetic revisions 
were made after Rounds 2 and 3, after pharmacists provided 
recommendations on using colour, font style and bolded and 
underlined text to emphasize and organize important ideas.
Implementing the pharmacist tools for medical abortion
Pharmacists identified 3 themes related to facilitators and bar-
riers to mifepristone/misoprostol dispensing in community 
pharmacies (Appendix 5, available online): 1) usability of the 
Checklist and Resource Guide; 2) the pharmacist’s role in abor-
tion provision; and 3) implementation of abortion services in 
community pharmacy practice.
Usability of the Checklist and Resource Guide. Pharmacists 
understood the intended use of the Checklist was to serve as a 
complete and concise summary of a pharmacist’s counselling 
responsibilities when dispensing mifepristone/misoprostol, 
while the Resource Guide provides background knowledge and 
rationale for each checklist item. One pharmacist described the 
resources as “suited for a pharmacist who has not . . . dispensed 
Mifegymiso [mifepristone/misoprostol]” (Participant 12, 
Round 3). Pharmacists appreciated the completeness of the 
resources, as one stated, “I think [the Checklist] has all the 
necessary information in order for the pharmacists to be able 
to do what they need to do” (Participant 2, Round 1). Another 
described the ease of use of these resources: “It’s a nice layout, 
the Checklist and then if you have any questions about the 
Checklist content, you can just refer to the Guide” (Participant 
10, Round 3). Additionally, community pharmacists emphasised 
the usefulness of having specific action-oriented steps for 
counselling patients, as one identified,
It’s nice to have a strict guideline. . . . Then I have confidence 
in telling them, “You can go [seek immediate help] if this is 
happening. This is what I mean by heavy bleeding. This is 
what I mean by a fever.” (Participant 6, Round 2)
Pharmacist’s role in abortion provision. When discussing 
performing a clinical assessment of the prescription and making 
therapeutic decisions, participants shared approaches for 
providing a prescription double-check to ensure it was necessary, 
effective and safe for the patient. When providing medication 
counselling, pharmacists described providing a treatment 
timeline and managing expected side effects, as one articulated, 
“This is when you can expect stuff to happen. This is how long it 
should last” (Participant 6, Round 2). When discussing abortion 
with patients, pharmacists recognized the importance of word 
choice in respectful health communication and appreciated its 
inclusion in the Resource Guide, as one pharmacist described,
I also like in your Guide the use of language and the 
communication about [abortion] because I see so many 
different situations with so many patients . . . and sensitivity 
with patients is essential. (Participant 12, Round 3)
Pharmacists described providing a pharmacist follow-up to 
support patients, noting the importance of obtaining consent 
for follow-up in this context. Moreover, when providing sup-
portive care and resources, pharmacists appreciated the “Cana-
dian Abortion Resources” in the Resource Guide that can be 
shared with patients and the “Supportive Care Checklist” in 
the Checklist summarizing critical nonpharmaceutical items 
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to review with patients (e.g., sanitary pads, contraceptive plan, 
personal support). One participant noted,
As a pharmacist, this is [information] that probably would 
have slipped my mind, so I think it’s good that it’s in [the 
Supportive Care Checklist]. (Participant 7, Round 2)
Finally, pharmacists shared finding innovative methods of sup-
porting patients, including using technology when encoun-
tering language barriers, employing telemedicine, shipping 
medications to patients in remote locations and providing a 
copy of the Checklist to patients.
Implementation of abortion services in community pharmacy 
practice. Pharmacists reported feeling underprepared to provide 
medical abortion. One pharmacist described feeling relieved 
to have the Checklist available when they first dispensed 
mifepristone/misoprostol:
I thought the checklist was really helpful. I wasn’t expecting 
a patient to show up and need me to counsel her . . . so 
having that checklist there was definitely a good fallback for 
me. It was very, very informative. (Participant 8, Round 3)
Several pharmacists shared using the resources as educational 
tools, including one who said, “With the other pharmacists 
[I trained], I basically gave them the Guide and asked them 
to read it” (Participant 11, Round 3), describing using the 
resources to frame discussions about medical abortion provi-
sion when training peers. When integrating the resources into 
their practice, pharmacists described where they would store 
the materials to facilitate others accessing the resources, includ-
ing printed copies in a designated folder in the pharmacy, with 
the medication, or in the counselling room, as well as online 
files saved on a shared computer server. In larger and busier 
pharmacies, some pharmacists described designating a phar-
macist expert to take charge of dispensing and counselling on 
medical abortion prescriptions. Pharmacists discussed using 
the Checklist to document counselling to enable referencing 
who dispensed the prescription and what was covered during 
patient counselling. Pharmacists did not foresee documenta-
tion becoming a regular part of their workflow unless it was 
mandated by the College of Pharmacists. Pharmacists identi-
fied scheduling time to provide counselling when working alone 
or in a busy pharmacy and using a private space for counselling, 
particularly at pharmacies lacking a private counselling area, 
as potential challenges to creating safe and supportive envi-
ronments for patient-pharmacist discussions. Moreover, they 
discussed issues related to working with prescribers, including 
limited provider training, inadequate communication between 
providers and pharmacists and the quality of provider coun-
selling to patients. Pharmacists indicated that the “Criteria 
for Medical Abortion” in the Resource Guide supported their 
understanding of a patient’s medical abortion care pathway 
and confirming patients receive the necessary information to 
make an informed choice.
Discussion
We developed a Pharmacist Checklist and Resource Guide to 
facilitate pharmacist provision of standardized informative 
medical abortion counselling to patients. Pharmacists found 
these resources easy to use and simple to integrate into tradi-
tional community pharmacy practice.
Validated usability scores suggest that our final mate-
rials are “Excellent” and reflect results from other user- 
centred design studies that developed and evaluated health care 
devices and decisions aids.22-24 Qualitative data facilitated our 
development process, ensured the inclusion of essential con-
tent and enhanced the systematic organization of the Checklist 
to reflect pharmacists’ structured dispensing thought process 
and the Resource Guide to resemble familiar drug monograph 
formatting. Iterative revisions allowed for gathering feedback 
on modifications and finetuning the final resources.
Our interviews elicited opportunities for pharmacists to 
provide compassionate and comprehensive care beyond sim-
ply counselling on medication effects. The Pharmacist Check-
list was recognized as a valuable tool for proactively facilitating 
discussions about timing treatment initiation within a patient’s 
lifestyle and ensuring a patient has all required treatment sup-
plies when leaving the pharmacy. Inclusive and patient-friendly 
language within the resources enables the respectful framing of 
conversations about abortion. Additional Canadian Abortion 
Resources in the Resource Guide provide helpful information 
for both health care professionals and patients. Counselling 
points within the Checklist provide opportunities to empower 
patients to actively participate in their care. Interventions, such 
as health professional training and patient decision aids, may 
improve patient participation and shared decision making.27 
Patient participation enables patients to make decisions align-
ing with their best interest, to share information with their 
health care provider and to ask for support when needed.28-30 
Positive relationships between patients and health care pro-
viders lead to better health outcomes, while education and 
counselling about medical abortion result in improved patient 
satisfaction.28 These pharmacist resources may be used in com-
bination with the Medical Abortion 101 visual infographic,31 
intended to be provided to patients when counselling on what 
to expect during medical abortion treatment.
Pharmacist interviews revealed barriers and facilitators to 
incorporating the pharmacy resources into Canadian com-
munity pharmacy practice. We found that pharmacists contin-
ued to experience barriers to provision even after prescribing 
restrictions were removed, such as lack of consistent messages 
from federal (i.e., Health Canada, Ministry of Health) and pro-
vincial (e.g., Colleges of Pharmacists and Physicians) regula-
tory bodies about the pharmacist’s role and responsibilities 
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in mifepristone/misoprostol provision. As medical abortion 
counselling may require additional time and resources inad-
equately reflected in a pharmacist’s dispensing fee, our data 
indicate this may act as an additional barrier to provision for 
some pharmacists. Ongoing research3,32-35 suggests that 3 years 
since mifepristone/misoprostol for medical abortion entered 
the Canadian market in January 2017, uptake continues to be 
variable across Canada.
Several pharmacy managers in our study reported using 
the Pharmacist Checklist and Resource Guide to train staff 
pharmacists for medical abortion provision. Indeed, a strength 
of our study was our integrated knowledge translation strat-
egy for engaging knowledge users throughout the research 
process. We provided participating pharmacists permission 
to use the materials and made the developing tools publicly 
available on the Canadian Abortion Providers Support web-
site in July 2018 after Round 1 evaluations and modifications. 
This allowed data collection from pharmacists who used the 
resources and incorporated them into their practice. Snowball 
sampling ensured that we recruited pharmacists with diverse 
exposures to mifepristone/misoprostol dispensing and unique 
insights into the pharmacist’s role in medical abortion provi-
sion. Nevertheless, as we recruited pharmacists practising in 
western Canadian regions, a limitation of our study was that 
our sample may not fully incorporate pharmacist experiences 
in more restrictive regions and provinces,32 such as Québec.33 
While our sample size did not allow for hypothesis testing of 
quantitative data, it reflected the size of similar qualitatively 
driven studies.22-24 We observed data saturation in Round 3 
evaluations with no new modifiable issues identified.
Conclusion
The Pharmacist Checklist and the Pharmacist Resource Guide 
for Medical Abortion have the potential to enhance the provision 
of pharmacist counselling for medical abortion in a wide range 
of practice settings, ensuring patients receive timely information 
and compassionate medical abortion care. The final products are 
available in English and French through the Canadian Abortion 
Providers Support (www.caps-cpca.ubc.ca) and the Canadian 
Pharmacists Association (www.pharmacists.ca) websites. ■
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